CHMP recommends drug interaction warnings for Victrelis
This article was originally published in Scrip
Executive Summary
Doctors treating patients with hepatitis C and HIV are being warned by the European Medicines Agency (EMA) that concentrations of ritonavir-boosted HIV protease inhibitors are reduced when given with Victrelis (boceprevir). The EMA is recommending that doctors do not co-administer Victrelis with ritonavir-boosted darunavir or lopinavir, while co-administration with ritonavir-boosted atazanavir may be considered on a case-by-case basis.